Physiogenex will be presenting the effects of semaglutide and lanifibranor in its innovative obese MASH/MetALD hamster model at the Keystone conference on Obesity in Vancouver, Canada, Feb. 4-7.
The abstract will be presented as a 10-min talk during the session “Response Environment” on Monday Feb. 5th 5pm-7pm and during the evening poster session on the same day by Dr. François Briand, our Director of Research and Business Development.
Unlike mouse and rat, the obese MASH hamster has a human-like lipoprotein/bile acids profile, shows evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis, and develops heart failure with preserved ejection fraction (HFpEF). The hamster also shows a high preference for alcohol, which makes an excellent model for the study of MetALD.
Reach out to François Briand during the meeting to learn how Physiogenex animal models and CRO services will drive your preclinical development of drugs targeting metabolic diseases to success.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.